Research programme: sickle cell anaemia therapy - Virginia Commonwealth University/Xechem
Alternative Names: 5-HMFLatest Information Update: 02 Oct 2021
At a glance
- Originator Virginia Commonwealth University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Sickle cell anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA (PO)
- 08 Jun 2006 5-HMF has received orphan drug status for sickle cell disease in the US
- 13 Dec 2005 Preclinical trials in Sickle cell anaemia in USA (unspecified route)